# Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes

> **NCT00971243** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 448 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** MP-513 Lowest Dose and Metformin
- **DRUG:** MP-513 Low Dose and Metformin
- **DRUG:** MP-513 Medium Dose and Metformin
- **DRUG:** MP-513 High Dose and Metformin
- **DRUG:** Placebo and Metformin

## Key facts

- **NCT ID:** NCT00971243
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 448 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00971243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00971243, "Efficacy and Safety of MP-513 in Combination With Metformin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00971243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*